Literature DB >> 25455465

Do we have a novel, clinically applicable approach to spinal cord protection?

John S Ikonomidis1.   

Abstract

Entities:  

Mesh:

Year:  2014        PMID: 25455465      PMCID: PMC4416785          DOI: 10.1016/j.jtcvs.2014.10.069

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  3 in total

1.  Spinal cord protection via alpha-2 agonist-mediated increase in glial cell-line-derived neurotrophic factor.

Authors:  Kirsten A Freeman; David A Fullerton; Lisa S Foley; Marshall T Bell; Joseph C Cleveland; Michael J Weyant; Joshua Mares; Xianzhong Meng; Ferenc Puskas; T Brett Reece
Journal:  J Thorac Cardiovasc Surg       Date:  2014-10-15       Impact factor: 5.209

2.  Attenuation of spinal cord ischemia and reperfusion injury by erythropoietin.

Authors:  Phillip D Smith; Ferenc Puskas; David A Fullerton; Xianzhong Meng; Doug Cho; Joseph C Cleveland; Michael J Weyant; T Brett Reece
Journal:  J Thorac Cardiovasc Surg       Date:  2011-01       Impact factor: 5.209

3.  Dexmedetomidine, an α-2a adrenergic agonist, promotes ischemic tolerance in a murine model of spinal cord ischemia-reperfusion.

Authors:  Marshall T Bell; Ferenc Puskas; Daine T Bennett; Paco S Herson; Nidia Quillinan; David A Fullerton; T Brett Reece
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-13       Impact factor: 5.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.